Kelzyn (Dienogest, Ethinylestradiol | Lactose)

Dienogest is a synthetic progestogen that binds to progesterone receptors, suppressing the mid‑cycle surge of luteinizing hormone and follicle‑stimulating hormone, thereby preventing ovulation. In combination with ethinylestradiol, it also induces changes in the endometrium and thickens cervical mucus, creating an environment that is unfavorable for fertilization and implantation.

The dosage regimen for Kelzyn is determined by the prescribing healthcare professional. Typically, the product is taken once daily at the same time for a 21‑day active phase followed by a 7‑day hormone‑free interval, but the exact schedule and any adjustments are individualized based on the patient’s medical history and response.

Kelzyn is intended for use by women who are not pregnant. If pregnancy occurs, the medication should be discontinued and alternative contraception considered. Use during breastfeeding is generally not recommended unless the benefits outweigh potential risks, and this decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Kelzyn product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details, and assists with any necessary import documentation.

Kelzyn contains dienogest, a progestogen with a relatively low androgenic profile, combined with ethinylestradiol, which may offer a favorable bleeding pattern and reduced risk of certain side effects compared with some older formulations that use levonorgestrel. However, efficacy, safety, and tolerability are comparable across approved combined pills, and the choice depends on individual patient factors and clinician judgment.

Kelzyn tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Kelzyn is taken orally, usually with water, once each day at the same time. The typical regimen consists of 21 consecutive days of active tablets followed by a 7‑day interval without active tablets, during which a withdrawal bleed occurs. Patients should not skip doses and should follow the schedule prescribed by their healthcare provider.

The most serious risks include thromboembolic events such as deep‑vein thrombosis, pulmonary embolism, stroke, and myocardial infarction, especially in women who smoke, have a history of clotting disorders, or possess cardiovascular risk factors. Rare cases of severe allergic reactions and liver dysfunction have also been reported. Prompt medical attention is required if symptoms of these conditions appear.

Kelzyn is contraindicated in women with a known hypersensitivity to any component, a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, breast cancer, or estrogen‑dependent tumors. It should also be avoided by smokers over 35 years of age and by those with migraine with aura. A thorough medical evaluation is essential before initiating therapy.